Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
Phase 2
Completed
- Conditions
- Hematologic NeoplasmsBone Marrow NeoplasmsNon-Hodgkin's Lymphoma
- Interventions
- Registration Number
- NCT00421213
- Lead Sponsor
- Alaunos Therapeutics
- Brief Summary
The study of safety of a new organic arsenic compound in the treatment of hematological malignancies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Single Arm Darinaparsin -
- Primary Outcome Measures
Name Time Method Response Rate 6 months
- Secondary Outcome Measures
Name Time Method toxicities 6 months